| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing …
Over the last 12 months, insiders at PDS Biotechnology Corporation have bought $0 and sold $0 worth of PDS Biotechnology Corporation stock.
On average, over the past 5 years, insiders at PDS Biotechnology Corporation have bought $38,930 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 15,061 shares for transaction amount of $25,001 was made by Glover Stephen C. (director) on 2025‑02‑28.
| 2025-02-28 | Glover Stephen C. | director | 15,061 0.0504% | $1.66 | $25,001 | -18.42% | ||
| 2025-02-28 | Freitag Gregory Gene | director | 15,060 0.0504% | $1.66 | $25,000 | -18.42% | ||
| 2021-12-13 | HILL MATTHEW C | 3,100 0.012% | $8.99 | $27,860 | -41.56% | |||
| 2021-06-16 | Bloomquist DeLyle W | 10,000 0.0456% | $9.88 | $98,778 | -4.17% | |||
| 2021-06-15 | Glover Steve C | 5,882 0.0235% | $8.50 | $49,997 | -2.50% | |||
| 2021-06-15 | Freitag Gregory Gene | 5,882 0.0235% | $8.50 | $49,997 | -2.50% | |||
| 2021-06-15 | VAN VOORHEES SETH | 17,647 0.0704% | $8.50 | $150,000 | -2.50% | |||
| 2021-06-15 | Ali-Jackson Kamil | 11,764 0.0469% | $8.50 | $99,994 | -2.50% | |||
| 2018-03-22 | Sale | Macdonald R. Loch | Chief Scientific Officer | 5,000 0.0161% | $16.41 | $82,050 | -94.86% | |
| 2018-03-21 | Sale | Macdonald R. Loch | Chief Scientific Officer | 5,000 0.0159% | $16.52 | $82,600 | -94.94% | |
| 2018-03-20 | Sale | Macdonald R. Loch | Chief Scientific Officer | 10,000 0.0322% | $16.47 | $164,700 | -94.85% | |
| 2018-03-19 | Sale | Macdonald R. Loch | Chief Scientific Officer | 5,000 0.0161% | $16.59 | $82,950 | -94.88% | |
| 2018-03-02 | Sale | Leuthner Brian A | President and CEO | 5,000 0.0159% | $15.08 | $75,400 | -94.24% | |
| 2018-03-01 | Sale | Leuthner Brian A | President and CEO | 5,000 0.0161% | $14.95 | $74,725 | -94.13% | |
| 2018-02-23 | Sale | Leuthner Brian A | President and CEO | 5,000 0.0158% | $15.37 | $76,850 | -94.34% | |
| 2018-02-22 | Sale | Macdonald R. Loch | Chief Scientific Officer | 5,000 0.0151% | $14.49 | $72,450 | -94.25% | |
| 2018-02-22 | Sale | Leuthner Brian A | President and CEO | 5,000 0.0161% | $15.42 | $77,100 | -94.25% | |
| 2018-02-21 | Sale | Macdonald R. Loch | Chief Scientific Officer | 10,000 0.0304% | $13.82 | $138,200 | -93.91% | |
| 2018-02-20 | Sale | Macdonald R. Loch | Chief Scientific Officer | 10,000 0.0323% | $13.79 | $137,850 | -93.48% | |
| 2018-02-02 | Sale | Leuthner Brian A | President and CEO | 5,000 0.0163% | $12.96 | $64,800 | -92.76% |
| HEALY JAMES | director | 2852711 5.111% | $4.02M | 2 | 0 | <0.0001% |
| Hove Anders D | director | 2021917 3.6225% | $2.85M | 1 | 0 | <0.0001% |
| BARER SOL J | director | 632810 1.1338% | $892,262.10 | 1 | 0 | <0.0001% |
| Bloomquist DeLyle W | 193888 0.3474% | $273,382.08 | 1 | 0 | <0.0001% | |
| Einhorn Andrew J. | Chief Financial Officer | 81941 0.1468% | $115,536.81 | 1 | 0 | <0.0001% |
| Glover Stephen C. | director | 78851 0.1413% | $111,179.91 | 2 | 0 | <0.0001% |
| Freitag Gregory Gene | director | 61213 0.1097% | $86,310.33 | 2 | 0 | <0.0001% |
| Spiegel Robert J. | director | 37112 0.0665% | $52,327.92 | 1 | 0 | <0.0001% |
| VAN VOORHEES SETH | 17647 0.0316% | $24,882.27 | 1 | 0 | <0.0001% | |
| Ali-Jackson Kamil | 11764 0.0211% | $16,587.24 | 1 | 0 | <0.0001% | |
| MIDDLEKAUFF W BRADFORD | Senior VP, GC and Secretary | 10000 0.0179% | $14,100.00 | 2 | 0 | +8.46% |
| LOUGHLIN JAMES J | director | 6000 0.0107% | $8,460.00 | 3 | 0 | 0% |
| HILL MATTHEW C | 4075 0.0073% | $5,745.75 | 1 | 0 | <0.0001% | |
| Faleck Herbert J | Chief Medical Officer | 500 0.0009% | $705.00 | 1 | 0 | <0.0001% |
| Vaish Renu | V.P., Global Reg. Affairs | 350 0.0006% | $493.50 | 1 | 0 | <0.0001% |
| MARCHIO ALBERT N II | Chief Accounting & Adm Officer | 0 0% | $0 | 1 | 3 | <0.0001% |
$9,405,928 | 107 | 12.61% | $74.85M | |
$1,701,941 | 56 | 17.58% | $93.09M | |
$66,137,559 | 49 | 6.29% | $89.66M | |
$19,705,388 | 47 | 86.26% | $67.15M | |
$77,146,704 | 43 | 13.28% | $93.12M |
| Increased Positions | 19 | +29.23% | 3M | +58.28% |
| Decreased Positions | 26 | -40% | 1M | -17.88% |
| New Positions | 7 | New | 3M | New |
| Sold Out Positions | 13 | Sold Out | 574,283 | Sold Out |
| Total Postitions | 58 | -10.77% | 8M | +40.4% |
| Vanguard Group Inc | $1,584.00 | 3.46% | 1.9M | -49,902 | -2.56% | 2025-09-30 |
| Blackrock, Inc. | $431.00 | 0.94% | 517,519 | +3,128 | +0.61% | 2025-09-30 |
| Geode Capital Management, Llc | $402.00 | 0.88% | 481,999 | +64,065 | +15.33% | 2025-09-30 |
| Citadel Advisors Llc | $322.00 | 0.7% | 386,430 | +137,405 | +55.18% | 2025-09-30 |
| Inspirion Wealth Advisors, Llc | $287.00 | 0.63% | 344,394 | +265,862 | +338.54% | 2025-09-30 |
| Squarepoint Ops Llc | $243.00 | 0.53% | 291,627 | +193,862 | +198.29% | 2025-09-30 |
| Renaissance Technologies Llc | $230.00 | 0.5% | 275,861 | +170,174 | +161.02% | 2025-09-30 |
| Blair William & Co/Il | $208.00 | 0.46% | 250,000 | 0 | 0% | 2025-09-30 |
| Ubs Group Ag | $167.00 | 0.36% | 200,236 | -342,785 | -63.13% | 2025-09-30 |
| State Street Corp | $111.00 | 0.24% | 133,333 | 0 | 0% | 2025-09-30 |